More info
Active ingredients
Sodium Heparin + Dexpanthenol + Troxerutin
Release form
Gel
Composition
1 tube contains: Troxerutin 2 g; dexpanthenol 5 g; sodium heparin 250 mg (30,000 me). Excipients: phenylethanol - 1 g, propylene glycol - 10 g, carbomer 940 or 980 - 800 mg, trometamol - 400 mg, purified water - up to 100 g
Pharmacological effect
Combined drug for external use. Heparin is an anticoagulant of direct action, a natural anti-clotting factor of the body. It has an anti-inflammatory effect, contributes to the regeneration of connective tissue by inhibiting the activity of hyaluronidase; inhibits thrombosis, activates the fibrinolytic properties of blood, improves local blood flow. Dexpanthenol - provitamin B5 - in the skin turns into pantothenic acid, which is part of coenzyme A, which plays an important role in the processes of acetylation and oxidation. Improving metabolic processes, dexpanthenol promotes the regeneration of damaged tissues; improves heparin absorption. Troxerutin is an angioprotective agent. It has P-vitamin activity, in particular, reduces vascular tissue permeability and capillary fragility, helps to normalize microcirculation and tissue trophism, reduces congestion in veins and paravenous tissues, has anti-edema and anti-inflammatory effects. In addition, due to the presence of preservative-antiseptic phenyl ethyl alcohol , the drug has a bactericidal and fungicidal effect, helping to prevent infection of the wound surface. The composition of the gel base provides the drug with moderate hyperosmolar properties.
Pharmacokinetics
Data on the pharmacokinetics of the drug Venolife; not provided.
Indications
Edema-pain syndrome and microcirculatory and trophic disorders caused by venous insufficiency of the lower extremities (varicose veins, acute and chronic thrombophlebitis, post-thrombophlebitis syndrome, chronic lymphostasis); soft tissue injuries (hematomas, dislocations, stretches); to accelerate granulation and epithelization of trophic ulcers in the regeneration phase (in the absence of pronounced exudation).
Contraindications
Open infected wounds or wounds with abundant exudation; hypersensitivity to the drug.
Precautionary measures
Do not use for intravaginal and rectal administration.
Use during pregnancy and lactation
Venolife; not contraindicated in pregnancy and lactation.
Dosage and administration
The gel is applied with a thin layer to the affected area and around it 2-3 times / day, evenly spreading over the skin surface with light rubbing movements until completely absorbed. The course of treatment is 2-3 weeks. The need for further treatment is determined by the attending physician, based on the severity of the pathological process and the results of clinical tests. When the disease recurs, the treatment can be carried out 2-3 times a year. if necessary, they are washed with 3% hydrogen peroxide solution, Furacilin 1: 5000 solution or 0.05% chlorhexidine digluconate solution and dried. The gel is applied in a uniform thin layer so that the entire affected surface is covered with the preparation, and a sterile gauze bandage is applied. Dressing change is carried out 1 time / day. With an open method of treatment, the drug is applied 1-2 times / day. The duration of treatment is determined by the dynamics of epithelialization.
Side effects
Allergic reactions: skin rash, itching (at the site of application of the drug).
Overdose
Currently, cases of drug overdose Venolayf; not reported.
Interaction with other drugs
The interaction of the drug with other drugs was not detected.
special instructions
Venolife; not intended for use in ophthalmology